Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas

• Status: Withdrawn
• Trial end date: 2013-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate whether therapy with farletuzumab is effective and safe in the treatment of resectable, non-functioning pituitary adenomas.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Morphotek
• Treatments: Farletuzumab

Criteria

Inclusion Criteria:

• Males and females >18 years old

• Diagnosis of non-functional pituitary adenoma

• Able and willing to undergo surgical resection of the pituitary tumor

• Significant medical conditions must be well-controlled and stable for at least 30 days prior to signing the informed consent form

Exclusion Criteria:

• Presence of clinically significant pituitary apoplexy

• Presence of hormone-secreting adenomas

• Presence of compressive optic neuropathy due to pituitary tumor

• No prior surgical, medical, or radiation therapy in the last 6 months